SAGILITY LIMITED (SAGILITY)
₹45.30 -0.66% last close, 16 Oct
Q2 FY27 results
📅 Next results: 22 Oct 2026 (board meeting)SAGILITY LIMITED's board meets on 22 Oct 2026 to consider its Q2 FY27 results (July-September 2026).
In its latest reported quarter, Q1 FY27, SAGILITY's revenue was ₹1,963 Cr (+27.6% year on year, -3.0% on the previous quarter), and net profit ₹217 Cr (+45.9% year on year); the operating margin was 22.3%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹1,963 | +27.6% | -3.0% |
| Operating profit | ₹438 | +26.6% | -9.7% |
| Net profit | ₹217 | +45.9% | -16.0% |
| EPS (₹) | 0.46 | +43.8% | -16.4% |
| Operating margin | 22.3% | — | — |
SAGILITY delivery percentage and open interest
NSE end-of-day data for
On Fri, 16 Oct 2026, 44.3% of the SAGILITY shares traded on NSE were taken to delivery, against the stock's own 20-session average of 43.89%. That is close to its usual level. In SAGILITY futures, open interest fell 1.75% while the futures price fell 0.81%: long unwinding (longs closing out).
Delivery in the last 5 sessions: 46.4% · 35.6% · 34.8% · 42.3% · 44.3%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Sagility Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate issued by Registrar and Transfer Agent MUFG Intime India Private Limited confirms that no requests for dematerialisation or rematerialisation were received during the period. This is a purely standard regulatory intimation with zero financial or operational bearing on the business.
- Compliance certificate submitted under Regulation 74(5) for the quarter ended September 30, 2026
- RTA MUFG Intime India confirmed zero demat/remat requests received during the quarter
- Filing submitted to BSE and NSE on October 13, 2026
Sagility Limited announced a change in its Senior Management Personnel (SMP) effective October 2, 2026. Mr. Daniel B. Bailey has resigned from his position as Global General Counsel due to personal reasons. In his place, the Board of Directors has approved the appointment of Mr. Brian Clayton as Global General Counsel. Mr. Clayton brings over 20 years of legal leadership experience from BPO and healthcare-focused roles, previously working at Omnicom Group and Conduent.
- Daniel B. Bailey resigned as Global General Counsel and SMP effective October 2, 2026
- Brian Clayton appointed as new Global General Counsel and SMP effective October 2, 2026
- Incoming counsel brings more than 2 decades of corporate legal, compliance, and privacy experience, including 20 years at Conduent
- Change formalised via resignation letter dated October 1, 2026
Sagility Limited has issued a communication to shareholders regarding the payment of the final dividend for FY 2025-26. The dividend was approved at Rs 0.10 per equity share of face value Rs 10 at the AGM held on August 20, 2026, with a record date of August 7, 2026. For shareholders whose electronic credit failed due to incorrect or incomplete bank account details, letters were dispatched on September 25, 2026, requesting updated KYC and bank details to release withheld payouts. The company also indicated that the relevant TDS return will be filed by October 31, 2026.
- Final dividend of Rs 0.10 per equity share declared for FY 2025-26
- Record date was Friday, August 7, 2026; AGM held on August 20, 2026
- Communication dispatched on September 25, 2026, to resolve rejected electronic transfers
- TDS returns for Q2 FY27 to be filed on or before October 31, 2026
Sagility Limited announced that company officials will participate in the 2026 Jefferies India Forum on Friday, September 18, 2026, at The Oberoi, Gurgaon. The interaction will involve multiple investors to discuss public-domain industry and business developments. The company explicitly stated that no unpublished price-sensitive information (UPSI) will be disclosed during the sessions.
- Conference scheduled for Friday, September 18, 2026
- Participating event: 2026 Jefferies India Forum held at The Oberoi, Gurgaon
- Nature of meet: Multiple investors group meetings
- No unpublished price-sensitive information (UPSI) will be shared
Sagility Limited announced that shareholders approved the re-appointment of Mr. Hari Gopalakrishnan (DIN: 03289463) at its 5th Annual General Meeting held on August 20, 2026. Mr. Gopalakrishnan, who retired by rotation under Section 152(6) of the Companies Act, 2013, continues as a Non-Executive Non-Independent Director. He has over 16 years of experience and is currently Partner and Global Co-Head of Services at BPEA EQT. The filing represents standard annual corporate governance compliance with no financial impact.
- Shareholders approved the re-appointment at the 5th AGM held on August 20, 2026
- Mr. Hari Gopalakrishnan re-appointed as Non-Executive Non-Independent Director retiring by rotation
- Director brings over 16 years of experience, associated with BPEA since 2007 and currently Partner at BPEA EQT
- Company confirmed the director is not debarred from holding office by any SEBI or statutory order
Sagility Limited announced the voting results of its 5th Annual General Meeting held on August 20, 2026. Shareholders approved all three ordinary resolutions with requisite majorities, including the adoption of FY26 financial statements and confirmation of a Rs 0.05 interim dividend along with a Rs 0.10 final dividend per equity share. The re-appointment of Non-Executive Director Hari Gopalakrishnan passed with 77.98% total votes in favor, though 61.91% of institutional votes were cast against the proposal. Total voter turnout stood at 79.09% of outstanding shares.
- Final dividend of Rs 0.10 per equity share approved, confirming total FY26 dividend payout alongside Rs 0.05 interim dividend
- Adoption of FY26 audited standalone and consolidated financial statements approved with 99.9999% votes in favour
- Re-appointment of Director Hari Gopalakrishnan passed with 77.98% total votes in favour, despite 61.91% institutional dissent
- Total voting participation reached 3,702,286,747 votes, representing 79.09% of outstanding share capital
Sagility Limited concluded its 5th Annual General Meeting (AGM) held on August 20, 2026, via video conferencing. Key agenda items transacted included the adoption of FY26 standalone and consolidated financial statements, re-appointment of director Mr. Hari Gopalakrishnan, and confirmation of an interim dividend of Rs 0.05 along with approval of a final dividend of Rs 0.10 per equity share. The voting results and Scrutinizer's report will be disclosed separately upon compilation.
- 5th AGM concluded on August 20, 2026, at 05:07 PM IST
- Shareholders transacted declaration of a final dividend of Rs 0.10 per equity share of Rs 10 each for FY26
- Confirmed interim dividend of Rs 0.05 per equity share paid during the financial year
- Adopted FY26 standalone and consolidated audited financial statements
Sagility Limited has announced its participation in the 'Emkay Confluence 2026 – India: Full Throttle Ahead' conference scheduled for August 13, 2026, in Mumbai. The company will engage in group and one-to-one meetings with institutional investors. Management has explicitly stated that no unpublished price-sensitive information (UPSI) will be shared, focusing instead on developments already in the public domain. This is a standard procedural disclosure for a company with a market capitalization of Rs 20,656 Cr.
- Investor conference scheduled for August 13, 2026, at Grand Hyatt, Mumbai.
- Company serves 6 of the top 10 healthcare payers in the United States.
- TTM revenue stands at Rs 7,193 Cr with an operating profit margin of 24.4%.
- Top 10 clients contribute over 90% of total revenue, indicating high concentration.
Sagility Limited has announced its 5th Annual General Meeting (AGM) to be held on August 20, 2026, via video conferencing. The company has dispatched letters to shareholders who have not registered their email addresses, providing access to the Annual Report for FY 2025-26. This follows a financial period where the company recorded a TTM revenue of ₹7,193 Cr and a PAT of ₹925 Cr. The cut-off date for identifying shareholders for this dispatch was July 24, 2026.
- 5th Annual General Meeting scheduled for August 20, 2026, at 04:00 p.m. IST
- Cut-off date for dispatching notices to unregistered email holders was July 24, 2026
- Company maintains a TTM revenue of ₹7,193 Cr with an operating profit margin of 24.4%
- Annual Report for FY 2025-26 is now publicly accessible via the company's investor relations portal
Sagility reported a strong start to FY27 with Q1 revenue reaching ₹1,963.5 crore, a 27.6% YoY increase. Adjusted PAT grew 35.1% YoY to ₹269.7 crore, maintaining a healthy 24% EBITDA margin despite absorbing statutory wage hikes in Karnataka and Telangana. The company signed $35.3 million in new steady-state Annual Contract Value (ACV) and successfully integrated the CareSeed acquisition, adding 26 mid-market clients. Management is pivoting towards outcome-driven managed service deals and leveraging its 'Sagility Synchrony' AI platform to drive operational efficiencies.
- Revenue grew 27.6% YoY to ₹1,963.5 crore ($207.8 million), with organic constant currency growth at 14.9%.
- Signed $35.3 million in steady-state ACV during the quarter across 18 existing clients and 1 new logo.
- Adjusted PAT increased 35.1% YoY to ₹269.7 crore, representing a 13.7% net margin.
- Voluntary attrition improved significantly to 28.6% from 38.1% in the preceding quarter (Q4 FY26).
- CareSeed acquisition (closed June 2026) added 26 new clients and specialized capabilities in Medicare Advantage quality reporting.
Sagility Limited has announced physical investor meetings in Mumbai scheduled for July 30 and 31, 2026. The company intends to reiterate existing public information regarding industry and company developments, ensuring no unpublished price-sensitive information is shared. This routine engagement follows a period where the company reported TTM revenue of ₹7,193 Cr and a healthy OPM of 24.4%. Investors should remain aware of the company's high client concentration, where the top 10 clients contribute over 90% of total revenue.
- Physical investor meetings scheduled for July 30 and 31, 2026, in Mumbai
- Company maintains a high client concentration with the top 3 customers generating ~65% of revenue
- Sagility serves 6 of the top 10 healthcare payers in the United States
- Current headcount stands at 44,185 employees following the addition of 4,300 people in H1 FY26
Sagility Limited has announced a schedule for physical investor meetings in Mumbai on July 30 and 31, 2026. The company clarified that these sessions will only reiterate information already in the public domain, ensuring no unpublished price-sensitive information (UPSI) is shared. This is a standard investor relations activity for a company with a market capitalization of ₹20,262 Cr and TTM revenue of ₹7,193 Cr. Investors should note that the schedule is subject to change due to exigencies.
- Physical investor meetings scheduled for July 30 and 31, 2026, in Mumbai.
- Company maintains a strong market position serving 6 of the top 10 healthcare payers in the US.
- TTM revenue as of the latest period stands at ₹7,193 Cr with an operating profit margin of 24.4%.
- Top 10 clients contribute over 90% of total revenue, highlighting significant client concentration.
- Promoter holding remains stable at 51.0% as of March 2026.
Sagility Limited has released its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, confirming its 100% revenue dependence on US healthcare exports. The company reported a consolidated turnover of ₹7,192.85 Cr and a large workforce of 46,860 permanent employees. A key metric for investors is the voluntary attrition rate, which increased to 29.4% in FY26 from 27.5% in FY25. The company maintains a high female workforce participation rate of 61.2% and spends 2.3% of its revenue on employee wellbeing measures.
- Total permanent employee count stood at 46,860 as of March 31, 2026, with 61.2% female representation.
- 100% of the ₹7,192.85 Cr consolidated turnover is derived from exports to the US healthcare industry.
- Voluntary attrition (for employees with >90 days tenure) rose to 29.4% in FY26 compared to 27.5% in FY25.
- Spending on employee wellbeing and safety measures accounted for 2.3% of total revenue.
- Direct sourcing from MSMEs and small producers accounted for 11.5% of total purchases by value.
Sagility Limited has issued a notice for its 5th Annual General Meeting (AGM) to be held on August 20, 2026. The company is seeking shareholder approval for a final dividend of ₹0.10 per share, which, combined with the ₹0.05 interim dividend paid in November 2025, brings the total FY26 dividend to ₹0.15 per share. The annual report highlights a significant headcount growth to 46,860 employees in FY26 from 38,316 in FY25. Other agenda items include the re-appointment of Non-Executive Director Mr. Hari Gopalakrishnan and the adoption of FY26 audited financial statements.
- Proposed final dividend of ₹0.10 per equity share of ₹10 face value for FY26
- Total employee headcount increased to 46,860 in FY26, up from 38,316 in the previous year
- Human rights training coverage for permanent employees improved to 96.2% in FY26 from 66.5% in FY25
- Top 10 clients contribute over 90% of total revenue, with top 3 generating approximately 65%
- AGM scheduled for August 20, 2026, at 4:00 PM IST via video conferencing
Sagility Limited has submitted its Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2026. The report confirms that the company's total issued and listed capital remains unchanged at 4,68,13,28,413 equity shares. Notably, 100% of the share capital is held in dematerialized form, with 89.16% in NSDL and 10.84% in CDSL. There were no changes in share capital during the quarter, and no demat requests were pending beyond the 21-day limit.
- Total issued and listed capital stands at 4,68,13,28,413 equity shares as of June 30, 2026
- 100% of the company's shares are held in dematerialized form, with zero shares in physical format
- NSDL holds the majority of demat shares at 89.16% (4,17,40,52,024 shares)
- CDSL holds 10.84% of the demat shares (50,72,76,389 shares)
- Zero demat requests were confirmed after 21 days or remained pending beyond the 21-day limit
Financial Performance
Revenue Growth by Segment
H1 FY26 revenue grew 25.5% YoY in INR terms (21.4% in constant currency); the company serves both Payer and Provider segments, with the Payer segment including 6 of the top 10 US Payers.
Geographic Revenue Split
100% of revenue is derived from the U.S. healthcare industry, making the company entirely dependent on the North American market.
Profitability Margins
Adjusted PAT margin improved to 14.6% in FY25 from 12.4% in FY24; Reported PAT margin increased to 9.7% in FY25 from 4.8% in FY24, driven by higher EBITDA and lower interest costs.
EBITDA Margin
Adjusted EBITDA margin was 26.4% in FY25 (up from 24.1% in FY24); the company has increased its FY26 guidance to close to 25% despite margin dilution from the BroadPath acquisition.
Capital Expenditure
Planned capital expenditure of approximately INR 200 Cr per annum for FY2025 and FY2026 to support technology investments and site expansions.
Credit Rating & Borrowing
Ratings upgraded to [ICRA]BBB (Stable)/[ICRA]A3+; unsecured borrowings reduced to INR 817 Cr in FY25 from INR 1,933.5 Cr in FY24 following debt-to-equity conversion.
Operational Drivers
Raw Materials
Specialized Healthcare Labor (44,185 employees) and IT Infrastructure/Software Licenses represent the primary cost components.
Import Sources
Talent is sourced from India (accounting for ~40% of the employee base), Philippines, Colombia, Jamaica, and the USA.
Key Suppliers
Sagility B.V. (Promoter financing) and Global Loan Agency Services Australia Nominees (Security Agent for lenders).
Capacity Expansion
Current headcount of 44,185 employees; added 4,300 people in H1 FY26 and 10 new sites in FY25 to support business growth.
Raw Material Costs
Employee costs are the primary driver; annualized attrition remained steady at 26.3% in H1 FY26, consistent with the previous year.
Manufacturing Efficiency
SLA compliance rate maintained above 95%, reflecting high operational execution and delivery efficiency.
Strategic Growth
Expected Growth Rate
21%
Growth Strategy
Achieving 21% growth through the integration of BroadPath to access the mid-market segment, leveraging GenAI to drive operational efficiencies and maintain ~25% EBITDA margins, and expanding clinical services and pharmacy benefit management.
Products & Services
Healthcare BPM services including claims processing, clinical management, pharmacy benefit management, and member enrollment/acquisition services.
Brand Portfolio
Sagility, BroadPath, DCI (Devlin Consulting Inc), and BirchAI.
New Products/Services
Expansion into tech-led BPaaS (Business Process as a Service) and GenAI-integrated healthcare solutions to enhance client engagement.
Market Expansion
Strategic entry into the mid-market segment through the BroadPath acquisition to broaden the client base beyond large Payers.
Market Share & Ranking
Serves 6 of the Top 10 healthcare Payers in the United States, indicating a strong market position in the consolidated Payer industry.
Strategic Alliances
Capability-led growth through the acquisitions of DCI, BirchAI, and BroadPath to strengthen healthcare domain leadership.
External Factors
Industry Trends
The US healthcare BPM industry is evolving towards tech-led BPaaS and automation; Sagility is positioning itself as a tech-led provider using GenAI.
Competitive Landscape
Operates in a consolidated Payer market with high barriers to entry; expanding into the mid-market to diversify competition.
Competitive Moat
High entry barriers due to complex US licensing (TPA) and regulatory requirements (HIPAA/HITRUST), combined with high client stickiness (95%+ SLA compliance).
Macro Economic Sensitivity
100% exposure to US healthcare market trends, regulatory shifts, and outsourcing decisions by US-based Payers and Providers.
Consumer Behavior
Revenue seasonality is driven by the US open enrollment period, typically resulting in stronger performance in Q3 and Q4 (53-54% of annual revenue).
Geopolitical Risks
Vulnerability to US regulatory changes (e.g., HIPAA) and economic conditions affecting the US healthcare outsourcing market.
Regulatory & Governance
Industry Regulations
Strict compliance required with US healthcare regulations including HIPAA, HITRUST, and Third-Party Administrator (TPA) licensing.
Environmental Compliance
ESG management system established and aligned to global reporting frameworks to monitor performance across operations.
Taxation Policy Impact
Deferred tax liability primarily relates to intangibles from acquisitions; deferred tax assets are linked to PPE and lease liabilities.
Risk Analysis
Key Uncertainties
100% revenue concentration in the US healthcare sector and 90% revenue concentration among the top 10 clients.
Geographic Concentration Risk
100% of revenue is generated from the United States market.
Third Party Dependencies
Significant dependency on the top 3 clients who contribute 65% of total revenue.
Technology Obsolescence Risk
Risk of falling behind in AI/GenAI adoption; mitigated by steady investments in tech-led transformation.
Credit & Counterparty Risk
Receivables risk mitigated by strong credit monitoring; Debtors' turnover ratio remains healthy at 6.44x.